Pyoderma gangrenosum
Pyoderma gangrenosum je rijetka, upalna bolest kože gdje bolne pustule ili čvorovi postaju čirevi koji progresivno rastu. Pyoderma gangrenosum nije zarazna. Tretmani mogu uključivati kortikosteroide, ciklosporin ili različita monoklonska antitijela. Iako može utjecati na ljude bilo koje dobi, uglavnom pogađa ljude u 40-im i 50-im godinama.
☆ U rezultatima Stiftung Warentest-a za 2022. iz Njemačke, zadovoljstvo potrošača ModelDerm-om bilo je samo nešto niže nego s plaćenim telemedicinskim konsultacijama.
Na nozi osobe sa ulceroznim kolitisom.
References
Pyoderma gangrenosum je rijetko stanje kože koje uzrokuje bolne čireve sa crvenim ili ljubičastim rubovima. Klasifikovana je kao upalna bolest i dio je grupe koja se zove neutrofilne dermatoze. Uzrok pyoderma gangrenosum je složen, uključuje probleme i s urođenim i sa adaptivnim imunitetom kod ljudi koji su genetski skloni. Nedavno su se istraživači fokusirali na folikul dlake kao potencijalnu početnu tačku bolesti.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum je rijetko stanje kože koje uzrokuje izuzetno bolne čireve. Iako ne razumijemo u potpunosti njegov uzrok, znamo da uključuje povećanu aktivnost određenih imunoloških stanica. Liječenje bolesti još uvijek nije lako. Imamo razne lijekove koji potiskuju imuni sistem ili modificiraju njegovu aktivnost. Pored toga, fokusiramo se i na liječenje rana i ublažavanje boli. Kortikosteroidi i ciklosporin su često prvi izbor za liječenje, ali u posljednje vrijeme postoji više istraživanja o korištenju bioloških terapija poput TNF-α inhibitora. Ovi biološki lijekovi se sve više preferiraju, posebno kod pacijenata s drugim upalnim stanjima, a koriste se i ranije u procesu bolesti.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
